Dr. Roch Doliveux

Roch Doliveux is Chairman of the GLG Institute, a community of accomplished executives exchanging experienced-based insight and Chairman of the Vlerick Business School. He is also Vice Chairman of the Board of the Pierre Fabre Group, the second largest dermo-cosmetics company in the world, and a member of the Board of Stryker, a leading medical technology company. Roch Doliveux also chairs the Caring Entrepreneurship Fund (King Baudouin Foundation), a philanthropic initiative which supports entrepreneurship in health and wellness.

Roch Doliveux was UCB's CEO from 2005 to 2014. Under his leadership the company transformed itself into is a patient-centric and innovation-driven global biopharmaceutical company focused on the discovery and development of novel medicines and solutions to transform the lives of people living with severe diseases. He succeeded in making UCB a company recognized for its attractive growth prospects and rich pipeline.
Roch Doliveux spent his entire career in the pharmaceutical industry. He first joined Ciba-Geigy (now Novartis) in Switzerland, Peru and France and then moved to Schering-Plough Corporation (now Merck & Co) in various positions in Belgium, France and the US, including President of Schering-Plough International. Before joining UCB, Roch Doliveux was Chief Executive Officer of Pierre Fabre Pharmaceuticals.

Doctor in Veterinarian Medicine from Maisons-Alfort (France), Roch Doliveux is also Laureate of the Faculty of Medicine, Créteil, and holds an MBA with distinction from INSEAD (France). Roch Doliveux was awarded the Doctor Honoris Causa degree of the University of Liège (Belgium) in October 2011 and was bestowed the title of Commander of the Order of the Crown by the Belgian government in November 2012.